Lacosamid Hikma

Lacosamide, the active ingredient in Lacosamid Hikma, is a sodium channel blocker presented as an intravenous solution for intravenous use. It belongs to the antiepileptic therapeutic class and is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this essential medication for qualified healthcare providers while ensuring consistent quality and regulatory compliance.

Lacosamide is used in the management of epilepsy, specifically targeting partial‑onset seizures.

Partial‑onset seizures in adults: Adjunctive therapy to reduce seizure frequency when added to existing antiepileptic regimens. Partial‑onset seizures in children (≥4 years): Adjunctive therapy to improve seizure control in pediatric patients. Epilepsy refractory to monotherapy: Used as part of combination therapy for patients whose seizures are not fully controlled by a single agent.

Lacosamide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness or imbalance. - Headache: Mild to moderate pain often reported during the initial treatment period. - Nausea: Gastrointestinal discomfort that may resolve with continued use. - Somnolence: Increased sleepiness, especially when combined with other CNS depressants. - Blurred vision: Temporary visual disturbances reported by some patients. - Fatigue: Generalized tiredness that may improve over time.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias requiring ECG monitoring. - Suicidal ideation: Emergence of depressive thoughts or behaviors necessitating psychiatric evaluation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: Marked reduction in breathing effort, particularly with concomitant depressants. - Hypotension: Significant drop in blood pressure, especially in rapid IV administration. - Anaphylaxis: Immediate hypersensitivity reaction with rash, airway compromise, or circulatory collapse.

When prescribing Lacosamide, clinicians should consider several safety measures.

Renal impairment: Adjust monitoring as the drug is primarily excreted unchanged by the kidneys. Hepatic impairment: Use with caution; hepatic dysfunction may alter drug handling. Cardiac conduction disorders: Perform baseline and periodic ECGs to detect PR‑interval changes. Concomitant CNS depressants: Observe for additive sedation or respiratory effects. Pregnancy: Risk category unknown; weigh potential benefits against possible fetal risks. Store at ambient temperature: Keep in the original container, protect from light and moisture.

Lacosamide can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): May exacerbate PR‑interval prolongation. - Carbamazepine: Can reduce lacosamide plasma concentrations, diminishing efficacy. - CYP2C19 inhibitors (e.g., fluconazole): May increase lacosamide exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate): May increase central nervous system depression. - Opioids: Additive sedation and respiratory depression risk. - Alcohol: Enhanced dizziness and coordination impairment. - CYP3A4 inducers (e.g., rifampin): May modestly lower lacosamide levels. - NSAIDs: Potential for increased gastrointestinal irritation when combined with nausea.